Together we are beating cancer

Donate now

Tim Gunn

Tim is a senior digital news officer at Cancer Research UK. He started writing about science after studying English literature at Cambridge and magazine journalism at City, University of London. Before joining the digital news team in August 2022, he was a journalist and medical magazine editor.
Tim Gunn
Showing 12 out of 35 results
Cells with nuclei in blue and mitochondria (energy factories) in green.

Our researchers have found mutations that make cancers much more likely to respond to immunotherapy. It's a chance to make breakthrough treatments work for many more people. Our researchers have found mutations that make cancers much more likely to respond to immunotherapy. It's a chance to make breakthrough treatments work for many more people.

by Tim Gunn | Analysis | 31 January 2024

31 January 2024

An image of a capsule sponge, a test for Barrett's oesophagus and oesophageal cancer

Our BEST4 trial will show if a capsule sponge test can be used to monitor people at high risk of oesophageal cancer. It could give the NHS a quick and simple new screening test for oesophageal cancer and save thousands of lives every year.  Our BEST4 trial will show if a capsule sponge test can be used to monitor people at high risk of oesophageal cancer. It could give the NHS a quick and simple new screening test for oesophageal cancer and save thousands of lives every year. 

by Tim Gunn | Analysis | 11 January 2024

11 January 2024

A Cancer Research UK-funded researcher in the lab.

We helped fund a trial into neuroblastoma treatment that has improved how doctors treat the disease when other options aren't working. It's an important step forward in treating these relapsed and refractory tumours, which have some of the lowest survival rates for any childhood cancer.   We helped fund a trial into neuroblastoma treatment that has improved how doctors treat the disease when other options aren't working. It's an important step forward in treating these relapsed and refractory tumours, which have some of the lowest survival rates for any childhood cancer.  

by Tim Gunn | News | 10 January 2024

10 January 2024

The International Agency for Research on Cancer's (IARC's) website, seen on a phone and a computer.

The International Agency for Research on Cancer has evaluated the risks of two types of forever chemical. Here's what the evidence tells us. The International Agency for Research on Cancer has evaluated the risks of two types of forever chemical. Here's what the evidence tells us.

by Tim Gunn, Sophie Brooks | News | 11 December 2023

11 December 2023

Two Cancer Research UK-funded researchers in their lab.

The MHRA has licensed anastrozole as a way to prevent breast cancer in almost 300,000 women. Our trial showed that it can halve their risk. The MHRA has licensed anastrozole as a way to prevent breast cancer in almost 300,000 women. Our trial showed that it can halve their risk.

by Tim Gunn | News | 7 November 2023

7 November 2023

A mouse-eared bat flying out of a cave

Bats rarely get cancer. They also resist viruses that kill humans, and some don't even seem to age. Scientists think that it might have something to do with their ability to fly – and that we can copy some of their tricks. Bats rarely get cancer. They also resist viruses that kill humans, and some don't even seem to age. Scientists think that it might have something to do with their ability to fly – and that we can copy some of their tricks.

by Tim Gunn | Analysis | 31 October 2023

31 October 2023

Cancer cells with extrachromosomal DNA (ecDNA)

Cancer Grand Challenges team eDyNAmiC has changed our understanding of how oesophageal cancer starts. In some cases, mutations scientists thought were a late effect of the disease could actually be driving it in the first place. The findings could give us a new way to intercept cancer before it becomes dangerous. Cancer Grand Challenges team eDyNAmiC has changed our understanding of how oesophageal cancer starts. In some cases, mutations scientists thought were a late effect of the disease could actually be driving it in the first place. The findings could give us a new way to intercept cancer before it becomes dangerous.

by Tim Gunn | In depth | 23 October 2023

23 October 2023

Steph Phillips, Dr Miriam Dixon-Zegeye & Professor Sarah Blagden

We're funding the UK's first precision cancer prevention trial unit. It's testing a drug that could help protect people with Li Fraumeni Syndrome, a genetic condition that can lead to a more than 90% lifetime risk of cancer, against the disease. We're funding the UK's first precision cancer prevention trial unit. It's testing a drug that could help protect people with Li Fraumeni Syndrome, a genetic condition that can lead to a more than 90% lifetime risk of cancer, against the disease.

by Tim Gunn | In depth | 19 September 2023

19 September 2023

Two cancer researchers looking at a cell image on screen

The UK is rejoining Horizon Europe, the EU’s £81bn flagship funding scheme for scientific research. The agreement will bring more funding for cancer researchers in the UK, as well as more opportunities for collaboration across Europe. The UK is rejoining Horizon Europe, the EU’s £81bn flagship funding scheme for scientific research. The agreement will bring more funding for cancer researchers in the UK, as well as more opportunities for collaboration across Europe.

by Tim Gunn | News | 7 September 2023

7 September 2023